Poor Demand for Its Covid Vaccine Prompts Novavax to Cut Sales Forecast

The vaccine maker reduced its 2022 guidance to a maximum of $2.3 billion, down from its previous estimate for as much as $5 billion.

The vaccine maker reduced its 2022 guidance to a maximum of $2.3 billion, down from its previous estimate for as much as $5 billion.

Source: Read More

PAID

Leave a Comment